Would an endotoxin test distinguish racemisation from a synthesis impurity in survodutide?

The case in front of me: an endotoxin test · racemisation · survodutide.

I suspect the honest answer is that it depends, in which case I would like to know on what.

Assume I can obtain either option without difficulty, so availability is not the deciding factor.

Is there a defensible reason to prefer one, or is this a coin flip?

The honest answer is that mapping is the only routine way to localise a substitution short of full sequencing.

A D-amino-acid substitution has an identical molecular weight to its L counterpart. It is invisible to intact mass, usually invisible to a routine gradient, and detectable by mapping combined with tandem fragmentation or by chiral analysis.

The relevant detail is that for a short peptide, trypsin may produce too few fragments to be useful. Chymotrypsin, Glu-C or a combination gives better coverage on sequences with few basic residues.

The caveat is that a map confirms sequence and says nothing about content, sterility or endotoxin.

Commission it on a first lot from a new supplier, not on every lot.

Answering this needs to know whether a mass-neutral substitution is plausible for the sequence, since that is the case mapping is for.

Cost is the practical objection. Mapping costs several times a purity assay, which is why it belongs on a first lot from a new supplier rather than on every lot.

Disulfide scrambling gives an unchanged intact mass with different connectivity. Non-reduced mapping — digesting without reducing first — is how the correct pairings are confirmed.

Non-reduced peptide mapping is the accepted approach to confirming disulfide connectivity.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Mapping is for mass-neutral problems. That is when it earns its cost.

The relevant limitation is that a mass-neutral substitution has the same molecular weight as the correct residue and can co-elute under a routine gradient.

Missed cleavages are normal and expected; a map with a moderate number of them is a normal map, not a failed one.

Coverage below about ninety-five per cent leaves real gaps, and the reported coverage figure should always accompany the conclusion.

Ask for the coverage figure with any map. Without it the result is not interpretable.

On the detail: this is the most informative single test available for a peptide identity question and it is rarely on a research-grade certificate.

Sequence coverage is the headline quality metric. Anything below about ninety-five per cent leaves regions unexamined, and the unexamined regions are where a problem could sit undetected.

D-amino-acid substitutions being mass-identical is the structural reason intact mass cannot detect them and mapping plus fragmentation can.

The caveat is that none of this makes a research-grade vial equivalent to a licensed medicine. There is no release testing programme behind it, no pharmacovigilance, and no recourse if it is wrong. Independent testing narrows your uncertainty; it does not eliminate the category difference.

A missing expected fragment is as informative as an unexpected one.